RE:Where do we go from here?The start of the anti-aging clinical trial is clearly a major achievement that normally would get rewarded and reflected in the share price. But I'm not so sure anymore.
R+F is known to be business predatores and Howard needed street cred badly after the previous failure trying to sell the compound without evidence of a clinical trial. Nevertheless, the terms were a disaster from a revenue perspective.
The market value potential they tend to attach to the compounds is not true, because the compounds will only cover a portion. It's nothing wrong with the compounds, because you cannot cover the whole market with a single compound. I want to know the realistic value instead, that would build confidence.
We don't know all terms of the abbvie deal, but when the up-front only can finance three months of operational cost it causes doubt.
In short, the track record is weak. We don't know if/when one should trust Howard.
Back to the clinical trial. The NR will trigger people to assess their investment, every NR does.
Until a new trustworthy management has been appointed it's very hard to say in which direction the share price go at the next NR. Maybe best case is zero reaction? I don't know. For the sake of my investment I'd like the share price to spike of course.
The management is pretty diluted. I'm surprised that the top-10 shareholders havn't teamed up to remove the existing management. Maybe they could get Geraldine on their side.